Insmed Incorporated (NASDAQ:INSM) Insider Martina M.D. Flammer Sells 37,828 Shares

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 37,828 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $78.61, for a total transaction of $2,973,659.08. Following the transaction, the insider now directly owns 100,165 shares of the company’s stock, valued at approximately $7,873,970.65. This represents a 27.41 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Martina M.D. Flammer also recently made the following trade(s):

• On Thursday, February 6th, Martina M.D. Flammer sold 33,055 shares of Insmed stock. The shares were sold at an average price of $80.90, for a total transaction of $2,674,149.50.
• On Tuesday, January 14th, Martina M.D. Flammer sold 1,384 shares of Insmed stock. The stock was sold at an average price of $68.72, for a total transaction of $95,108.48.
• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The shares were sold at an average price of $63.64, for a total value of $392,786.08.
• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The shares were sold at an average price of $65.91, for a total value of $220,403.04.

Insmed Stock Down 0.4 %

Insmed stock traded down $0.29 during trading hours on Wednesday, hitting $79.60. 1,389,754 shares of the stock traded hands, compared to its average volume of 1,907,916. Insmed Incorporated has a one year low of $21.92 and a one year high of $82.04. The firm’s 50-day moving average price is $73.15 and its two-hundred day moving average price is $73.16. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market cap of $14.24 billion, a PE ratio of -14.34 and a beta of 1.11.

Institutional Investors Weigh In On Insmed

Several hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC raised its holdings in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares in the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of Insmed in the 3rd quarter worth about $30,000. GAMMA Investing LLC increased its stake in shares of Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares in the last quarter. Spire Wealth Management purchased a new position in Insmed during the 4th quarter valued at about $47,000. Finally, Exchange Traded Concepts LLC boosted its stake in Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 627 shares in the last quarter.

Wall Street Analyst Weigh In

INSM has been the subject of several recent research reports. Morgan Stanley boosted their price target on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Guggenheim increased their price objective on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research note on Friday, February 7th. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Insmed in a research note on Friday, November 1st. JPMorgan Chase & Co. increased their price target on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. Finally, Stifel Nicolaus boosted their price objective on shares of Insmed from $88.00 to $97.00 and gave the company a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Insmed presently has an average rating of “Moderate Buy” and an average price target of $85.60.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.